(R)- (11C)1- (2- chlorophenyl)- N- methyl- N- (1- methylpropyl)- 3- isoquinolinecarboxamide

Subscribe to Selected New Research on (R)-(11C)1-(2-chlorophenyl)-N-methyl-N-(1-methylpropyl)-3-isoquinolinecarboxamide

11 relevant articles (0 outcomes, 5 trials/studies) found for this Bio-Agent

Description: a radiopharmaceutical compound

Also Known As:

(11C)PK11195; (R)-(11C)PK11195

Bio-Agent Context: Research Results

Organic Chemicals: 40

Amides: 145

(R)-(11C)1-(2-chlorophenyl)-N-methyl-N-(1-methylpropyl)-3-isoquinolinecarboxamide: 11

Heterocyclic Compounds: 23

2-Ring Heterocyclic Compounds

Isoquinolines: 17

(R)-(11C)1-(2-chlorophenyl)-N-methyl-N-(1-methylpropyl)-3-isoquinolinecarboxamide: 11

Experts

1.	Gulyás, Balázs: 1 article (01/2008)
2.	Halldin, Christer: 1 article (01/2008)
3.	Vas, Adám: 1 article (01/2008)
4.	Hillert, Jan: 1 article (01/2008)
5.	Karrenbauer, Virginija D: 1 article (01/2008)
6.	Cselényi, Zsolt: 1 article (01/2008)
7.	Shchukin, Yevgeni: 1 article (01/2008)
8.	Savic, Ivanka: 1 article (01/2008)
9.	Kostulas, Kosta: 1 article (01/2008)
10.	Takano, Akihiro: 1 article (01/2008)

Related Diseases

1.	Multiple Sclerosis 05/01/2003 - "PET visualization of microglia in multiple sclerosis patients using [11C]PK11195." 01/15/2008 - "Functional neuroimaging in multiple sclerosis with radiolabelled glia markers: preliminary comparative PET studies with [11C]vinpocetine and [11C]PK11195 in patients." 09/01/2002 - "Semiquantification of the peripheral-type benzodiazepine ligand [11C]PK11195 in normal human brain and application in multiple sclerosis patients." 04/01/2005 - "OBJECTIVE: The objectives of the present study were to assess brain atrophy in multiple sclerosis (MS) patients during different disease stages and to investigate by PET and [11C]PK11195, a marker of microglial activation, the relationship between inflammation, atrophy and clinically relevant measures" Get all the results and reference details, order at left...
2.	Inflammation 09/01/2002 - "OBJECTIVES: [11C]PK11195 is a peripheral-benzodiazepine-receptor radioligand used for detection of microglial inflammation" 04/01/2005 - "OBJECTIVE: The objectives of the present study were to assess brain atrophy in multiple sclerosis (MS) patients during different disease stages and to investigate by PET and [11C]PK11195, a marker of microglial activation, the relationship between inflammation, atrophy and clinically relevant measures" Get all the results and reference details, order at left...
3.	Liver Failure 08/01/2002 - "Preliminary reports suggest that positron emission tomography (PET) studies using [11C]-PK11195 may be useful for the assessment of the neurological consequences of chronic liver failure." Get all the results and reference details, order at left...
4.	Schizophrenia (Dementia Praecox) 11/01/2008 - "Microglia activation in recent-onset schizophrenia: a quantitative (R)-[11C]PK11195 positron emission tomography study." Get all the results and reference details, order at left...
5.	Parkinson Disease (Parkinson's Disease) 10/15/2007 - "Neuroinflammation in the pathophysiology of Parkinson's disease: evidence from animal models to human in vivo studies with [11C]-PK11195 PET." Get all the results and reference details, order at left...
12 Diseases and 11 more articles analyzed in the Research Interface, order at left...

Related Drugs and Biologics

1.	vinpocetine
2.	GABA-A Receptors (GABA(A) Receptor)
3.	Benzodiazepines
3 Drugs and Important Bio-Agents and 2 more articles analyzed in the Research Interface, order at left...

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License details >>

Price:

$490.00 access via web interface, 1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m", 1 year subscription

Proceed to Checkout >>